TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-γ and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm

Clinical and Experimental Immunology

Volumn 138, Issue 3, 2004, Pages 417-422

  Nagayama, Yuji ^a   Saitoh, O ^a   McLachlan, S M ^c   Rapoport, B ^c   Kano, H ^b   Kumazawa, Y ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Graves' hyperthyroidism; Knockout mice; Th1 Th2; Thyrotropin receptor

Indexed keywords

ADENOVIRUS VECTOR; GALACTOSYLCERAMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HELMINTH; IMMUNE RESPONSE; KNOCKOUT MOUSE; LYMPHOMA CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SPLEEN CELL; TH1 CELL; TH2 CELL; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOANTIBODIES; FEMALE; GRAVES DISEASE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, THYROID-STIMULATING; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES, HELPER-INDUCER; TH1 CELLS; TH2 CELLS; THYROXINE; VIRAL PROTEINS;

EID: 9644302962     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02641.x     Document Type: Article

References (34)

1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor, interaction with TSH and autoantibodies. Endocr Rev 1998; 19:673-716.
2. Nagayama Y, Kita-Furuyama M, Nakao K, Ando T, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing thyrotropin receptor. J Immunol 2002; 168:2789-94.
3. Kaithamana S, Fan J, Osuga Y, Liang S-G, Prabhakar BS. Induction of experimental autoimmune Graves' disease in BALB/c mice. J Immunol 1999; 163:5157-64.
4. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice by IL-4, a Th2 cytokine. J Immunol 2003; 170:3522-7.
5. Dogan R-NE, Vasu C, Holterman MJ, Prabhakar BS. Absence of IL-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves' disease. J Immunol 2003; 170:2195-204.
6. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B. Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 suppression in a mouse model of Graves' hyperthyroidism. J Immunol 2004; 173:2167-73.
7. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 2003; 111:1897-904.
8. Andoh A, Masuda A, Kumazawa Y, Kasajima T. Serum antibody response and nasal lymphoid tissue (NALT) structure in the absence of IL-4 or IFN-γ. Cytokine 2002; 20:107-12.
9. Nagayama Y, McLachlan SM, Rapoport B, Niwa M. A major role for non-major histocompatibility complex genes but not for microorganisms in a novel murine model of Graves' hyperthyroidism. Thyroid 2003; 13:233-8.
10. Barrett K, Liakata E, Rao PV, Watson PF, Weetman AP, Lymberi P, Banga JP, Carayanniotis G. Induction of hyperthyroidism in mice by intradermal immunization with DNA encoding the thyrotropin receptor. Clin Exp Immunol 2004; 136:413-22.
11. Shimojo N, Kohno Y, Yamaguchi K et al. Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci USA 1996; 93:11074-9.
12. Land KJ, Moll JS, Kaplan MH, Seetharamaiah GS. Stat6- but not Stat4-dependent immunity is required for the development of autoimmunity in Graves' hyperthyroidism. Endocrinology 2004; 145:3724-30.
13. Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med 1997; 185:1039-41.
14. Peng SL, Moslehi J, Craft J. Roles of interferon-γ and interleukin-4 in murine lupus. J Clin Invest 1997; 99:1936-46.
15. Haas C, Ryffel B, Hir ML. IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW) F1 mice. J Immunol 1998; 160:3713-8.
16. Balasa B, Deng C, Lee J, Bradley LM, Dalton DL, Christadoss P, Sarvetnick N. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997; 186:385-91.
17. Zhang G-X, Xiao B-G, Bai X-F, van der Meide PH, Orn A, Link H. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 1999; 162:3775-81.
18. Ostlie N, Milani M, Wang W, Okita D, Conti-Fine BM. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 2003; 170:604-12.
19. Hultgren B, Huang X, Dybdal N, Stewart TA. Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45:812-7.
20. von Herrath MG, Oldstone MBA. Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185:531-9.
21. Radu D, Noben-Trauth N, Hu-Li J, Paul WE, Bona CA. A targeted mutation in the IL-4Rα gene protects mice against autoimmune diabetes. Proc Natl Acad Sci USA 2000; 97:12700-4.
22. Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol 2002; 102:185-91.
23. Manoury-Schwartz B, Chiocchia G, Bessis N et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J Immunol 1997; 158:5501-6.
24. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J Immunol 1997; 158:5507-13.
25. Liblau R, Steinman L, Brocke S. Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int Immunol 1997; 9:799-803.
26. Krakowski M, Owens T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26:1641-6.
27. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalitis. J Immunol 1996; 156:5-7.
28. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan C-C, Wiggert B, Caspi R. IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of deviant effector response. J Immnuol 1997; 158:5997-6005.
29. Alimi E, Huang S, Brazillet M-R, Charreire J. Experimental autoimmune thyroiditis (EAT) in mice lacking the IFN-γ receptor gene. Eur J Immunol 1998; 28:201-8.
30. Tang H, Sharp GC, Peterson KE, Braley-Mullen H. Induction of granulomatous experimental autoimmune thyroiditis in IL-4 gene-disrupted mice. J Immunol 1998; 160:155-62.
31. H1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nature Immunol 2001; 2:1054-60.
32. Rhodes SG, Graham S. Is timing important for cytokine polarization? Trend Immunol 2002; 23:246-9.
33. Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14:15-7.
34. Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM. γ-interferon is one of several direct B cell-maturing lymphokines. Nature 1984; 309:801-4.